Webinar : Organ-on-chips including BIOMIMESYS® for toxicology and oncology programmes, December 14 & 16

Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into account flux-related aspects. BIOMIMESYS® being an ideal hydroscaffold™ for 3D cell culture, this webinar aims Read more…

Poster (OncoLilleDays2022) – Mechanobiological characterization of a 3D in vitro pancreatic ductal adenocarcinoma model and the study of tumor-stroma interaction

Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a microfluidic chip to co-culture Cancer-Associated fibroblasts and cancerous cells, with the aim to increase the Read more…

Poster – Including the matricial tumoral microenvironment in 3D in vitro models by using a Hyaluronic-Acid-based hydroscaffold™

Abstract: In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and Read more…

Healthcare or how to find new treatments: History (hasardous), today (inefficient) and future (with BIOMIMESYS®)

In this presentation, Nathalie MAUBON (CEO HCS Pharma), give an overview of drugs discovery, from pre-19th century are, where trials are done on humans, to nowadays where clinical trials are safer but with a dramatic rate of failure. She explains what are the “target base screening” and the “phenotypic screening Read more…

Importance du microenvironnement dans les modèles cérébraux in vitro pour le criblage phénotypique

Presentation in english Environ 90 % des candidats médicaments échouent aux essais cliniques, notamment en neurologie, faute d’efficacité. Cela met en évidence un manque de pertinence dans les modèles précliniques, y compris les modèles in vitro, qui ne prennent pas en compte le microenvironnement, composé par les cellules gliales et Read more…

[job] Contrat d’apprentissage en commerce de produits et de services en pharmacologie et toxicologie

HCS Pharma est une start-up biotechnologie créée en 2014, installée au Biocentre Fleming (derrière le CHR et le parc Eurasanté, à Loos). Dans le cadre de son développement commercial, HCS Pharma recherche un(e) étudiant(e) en alternance en commerce pour vendre les produits de sa gamme BIOMIMESYS® pour la culture cellulaire Read more…

Poster – (ECM 2022) Development of innovative hiPSC-based model including an innovative 3D modified hyaluronic acid hydroscaffold for phenotypic screening

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and Read more…